JO3088B1 - مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف - Google Patents

مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف

Info

Publication number
JO3088B1
JO3088B1 JOP/2005/0188A JOP20050188A JO3088B1 JO 3088 B1 JO3088 B1 JO 3088B1 JO P20050188 A JOP20050188 A JO P20050188A JO 3088 B1 JO3088 B1 JO 3088B1
Authority
JO
Jordan
Prior art keywords
alkyl
alkyloxy
hydrogen
5alkyl
2alkyl
Prior art date
Application number
JOP/2005/0188A
Other languages
English (en)
Inventor
Papanikos Alexandra
Jean Edgard Freyne Eddy
Ten Holte Peter
Henri Storck Pierre
Sophie Poncelet Virginie
Willems Marc
Constant Johan Embrechts Werner
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3088B1 publication Critical patent/JO3088B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات ( compounds) من الصيغه باشكال N- اوكسيد( N-oxide forms) باملاح الاضافة( addition salts) المقبولة دوائيا وبالاشكال الايزومرية الكيميائية الفراغية ( stereochemically isomeric forms) منها حيث: Z يمثل NH Y يمثل C3-9 الكيل( C3-9alkyl) ، c1-5 الكيل C1-5NR13 الكيل، ( C1-5alkyl – NR13-C1-5alkyl) C1-5 الكيل C1-5-CO-NR14 الكيل- ( C1-5alkyl –NR14-CO-C1-5alkyl) C1-2 الكيل C1-3 NH-CO-CH2-NR21 الكيل – (C1-2ALKYL-NR21-CH2-CO-NH-C1-3alkyl) او C1-2 الكيل NH-CR16R17-CO-NR23 ) (C1-2alkyl-NR23-CO-CR16R17-NH X1 يمثل O او C1-2 O الكيل( O-C1-2alkyl-) X2 يمثل رابطة مباشرة ( direct bond) C1-2 الكيل ( C1-2alkyl)، c1-2 co الكيل ( -CO-C1-2alkyl) او C1-2NR12 الكيل ( NR12C1-2alkyl) R1 يمثل هيدروجين ( hydrogen ) او هالو ( halo) R2 يمثل هالو ( halo) استيلين ( acetylene) او Het1 R3 يمثل هيدروجين ( hydrogen) او سيانو ( cyano) R4 يمثل C1-4-Ar4 الكيل اوكسي ( Ar4-C1-4alkoxy) C1-4 الكيل اوكسي (C1-4alkoxy) او C1-4 الكيل اوكسي (C1-4alkoxy) مستبدل مع بديل واحد او اذا امكن مع اثنين او اكثر من بدائل مختراة من Het2 ، NR7R8 هيدروكسي ( hydroxy) و C1-4 الكيل اوكسي C1-4 الكيل اوكسي ( C1-4alkyloxy – C1-4alkyoxy) R7 يمثل هيدروجين ( hydrogen) او c1-4 الكيل( C1-4 alkyl) R8 يمثل c1-4 الكيل( c1-4alkyl) مستبدل مع NR25R26 او C1-4 الكيل سلفونيل ( C1-4 alkylsulfonyl ) R12 يمثل هيدرويجين ( hydrogen) او C1-4 الكيل –( C1-4 alkyl) R13 يمثل AR6 سلفونيل ( AR6-sulfonyl) او C1-6 الكيل اوكسي كربونيل ( C1-6 alkyloxycarbonyl) مستبدل اختياريا مع فنيل ( phenyl) R16 و R17 يمثلان هيدروجين ( hydrogen) C1-4 الكيل( C1-4 alkyl) او يؤخذ R16 و R17 معا مع ذرة الكربون ( carbon atom) المرتبطة معها لتشكيل C3-6 الكيل دائري( C3-6 cycloakyl) R23 يمثل c1-4 الكيل ( C1-4alkyl) و R23 يمثل هيدروجين ( hydrogen) عنما يؤخذ r16 و r17 معا مع ذرة الكربون ( carbon atom) المرتبطة معهما لتشكيل c3-6 الكيل دائري ( C3-6cycloalkyl) R27,R26,R25 و R28 كل منهم على حدة يمثل هيدروجين ( hydrogen) او C1-4 الكيل كربونيل( C1-4alkylcarbonyl) Het1 يمثل 2- بورا-1، 3 ثنائي اوكسولانيل( 2-boro 1.3-dioxolanyl) Het2 يمثل بيبريدينيل ( piperidiny
JOP/2005/0188A 2004-12-08 2005-11-28 مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف JO3088B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04106383 2004-12-08

Publications (1)

Publication Number Publication Date
JO3088B1 true JO3088B1 (ar) 2017-03-15

Family

ID=34930015

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2005/0188A JO3088B1 (ar) 2004-12-08 2005-11-28 مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف

Country Status (22)

Country Link
US (1) US20100152174A1 (ar)
EP (1) EP1828201B1 (ar)
JP (1) JP5140431B2 (ar)
KR (1) KR101320431B1 (ar)
CN (2) CN102532163B (ar)
AR (1) AR051985A1 (ar)
AU (1) AU2005313350B2 (ar)
BR (1) BRPI0518394B8 (ar)
CA (1) CA2588764C (ar)
DK (1) DK1828201T3 (ar)
EA (1) EA013995B1 (ar)
ES (1) ES2559305T3 (ar)
HU (1) HUE027253T2 (ar)
JO (1) JO3088B1 (ar)
MX (1) MX2007006820A (ar)
MY (1) MY148503A (ar)
NZ (1) NZ555496A (ar)
PA (1) PA8654501A1 (ar)
SI (1) SI1828201T1 (ar)
TW (2) TWI432440B (ar)
UA (1) UA91522C2 (ar)
WO (1) WO2006061417A2 (ar)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
EP1697384B1 (en) * 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
EP2044084B1 (en) * 2006-07-13 2016-02-17 Janssen Pharmaceutica NV Mtki quinazoline derivatives
MX2009004436A (es) * 2006-10-27 2009-05-22 Janssen Pharmaceutica Nv Derivados de quinazolina macrociclicos como inhibidores del factor de crecimiento endotelial vascular r3.
EA200970420A1 (ru) * 2006-10-27 2009-12-30 Янссен Фармацевтика Нв Применение mtki 1 для лечения или предупреждения рака кости
CA2687909C (en) * 2007-06-21 2015-09-15 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
US8318731B2 (en) 2007-07-27 2012-11-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
DK2350075T3 (da) 2008-09-22 2014-05-26 Array Biopharma Inc Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
PT3106463T (pt) 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
RU2735545C2 (ru) * 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
KR101927114B1 (ko) * 2014-02-07 2018-12-10 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
EP3218380B1 (en) 2014-11-16 2021-03-17 Array Biopharma, Inc. Preparation of a crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
IL304018A (en) 2016-04-04 2023-08-01 Loxo Oncology Inc Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2952056T3 (es) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2423536A1 (de) * 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
US4126688A (en) * 1976-05-17 1978-11-21 Janssen Pharmaceutica N.V. Antiemetic 1-(benzotriazolyl-alkyl)-piperidine derivatives
US4442278A (en) * 1981-12-03 1984-04-10 Hughes Aircraft Company Ethynyl-substituted s-triazine derivatives, polymers thereof and process for making the same
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
CA2137203C (en) * 1993-12-07 2006-11-28 William Francis Heath Jr. Protein kinase c inhibitors
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
DE69502028T2 (de) * 1994-10-31 1998-12-10 Dsm N.V., Heerlen Katalytische zusammensetzung und verfahren zur olefinpolymerisation
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EA199800372A1 (ru) * 1995-11-14 1998-10-29 Дзе Дюпон Мерк Фармасьютикал Компани Новые макроциклические соединения-ингибиторы
DE19608588A1 (de) * 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HU228446B1 (en) * 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
AU6998000A (en) * 1999-08-27 2001-03-26 Boehringer Ingelheim Pharma Kg Substituted indolinones as tyrosine kinase inhibitors
ATE396978T1 (de) * 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
US6864255B2 (en) * 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
BR0210391A (pt) * 2001-06-12 2004-06-15 Elan Pharm Inc Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
ATE341545T1 (de) * 2001-07-16 2006-10-15 Astrazeneca Ab Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7504408B2 (en) * 2002-07-09 2009-03-17 Astrazeneca Ab Quinzoline derivatives for use in the treatment of cancer
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US20050021480A1 (en) * 2003-05-16 2005-01-27 Hyperspace Communications, Inc. Method and apparatus for creating and validating an encrypted digital receipt for third-party electronic commerce transactions
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
ES2335216T3 (es) * 2003-12-18 2010-03-23 Janssen Pharmaceutica Nv Derivados de 3-ciano-quinolina con actividad antiproliferativa.
EP1697384B1 (en) * 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
US8778919B2 (en) * 2005-06-30 2014-07-15 Janssen Pharmaceutica Nv Cyclic anilino—pyridinotriazines
EP1951729B1 (en) * 2005-11-16 2014-06-25 Cell Therapeutics, Inc. Oxygen linked pyrimidine derivatives
EP2044084B1 (en) * 2006-07-13 2016-02-17 Janssen Pharmaceutica NV Mtki quinazoline derivatives
CA2687909C (en) * 2007-06-21 2015-09-15 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
US8318731B2 (en) * 2007-07-27 2012-11-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
EP2283024B1 (en) * 2008-03-10 2013-05-15 Janssen Pharmaceutica, N.V. 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors

Also Published As

Publication number Publication date
CN101072781B (zh) 2012-07-18
TW201410684A (zh) 2014-03-16
NZ555496A (en) 2011-04-29
ES2559305T3 (es) 2016-02-11
BRPI0518394B8 (pt) 2021-05-25
SI1828201T1 (sl) 2016-02-29
BRPI0518394B1 (pt) 2020-12-15
TW200635933A (en) 2006-10-16
PA8654501A1 (es) 2006-09-08
EA013995B1 (ru) 2010-08-30
KR101320431B1 (ko) 2013-10-30
WO2006061417A2 (en) 2006-06-15
TWI432440B (zh) 2014-04-01
EA200701233A1 (ru) 2007-10-26
UA91522C2 (en) 2010-08-10
KR20070086030A (ko) 2007-08-27
AR051985A1 (es) 2007-02-21
AU2005313350B2 (en) 2012-05-31
WO2006061417A3 (en) 2006-08-03
CN102532163B (zh) 2016-06-01
US20100152174A1 (en) 2010-06-17
JP2008523034A (ja) 2008-07-03
BRPI0518394A2 (pt) 2008-11-18
HUE027253T2 (en) 2016-08-29
DK1828201T3 (en) 2016-02-01
TWI511970B (zh) 2015-12-11
JP5140431B2 (ja) 2013-02-06
EP1828201A2 (en) 2007-09-05
MY148503A (en) 2013-04-30
AU2005313350A1 (en) 2006-06-15
MX2007006820A (es) 2007-07-24
CN102532163A (zh) 2012-07-04
CA2588764A1 (en) 2006-06-15
CA2588764C (en) 2016-11-29
CN101072781A (zh) 2007-11-14
EP1828201B1 (en) 2015-11-11

Similar Documents

Publication Publication Date Title
JO3088B1 (ar) مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
WO2007003525A3 (en) Cyclic anilino-pyridinotriazines as gsk-3 inhibitors
CY1121051T1 (el) Περιεχουσα αζωτο ετεροκυκλικη ενωση και γεωργικο/κηπουρικο σποριοκτονο
ECSP077274A (es) Derivados de n-2 adamantanil-2-fenoxi-acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide
EA200501045A1 (ru) Адамантилацетамиды как ингибиторы 11-бета гидроксистероиддегидрогеназы
UA98116C2 (ru) Изоксазолины, композиция, их применение, способы получения и промежуточные соединения
MX2009008325A (es) Herbicidas con n-oxido de piridina sustituido.
HRP20080113T3 (hr) Supstituirani piridinilni i pirimidinilni derivati kao modulatori metabolizma i liječenje bolesti koje su s tim povezane
TN2012000033A1 (en) Mixtures of mesoionic pesticides
PH12013501489A1 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
NO20056196L (no) Makrocykliske kinazolinderivater som antiproliferative midler
EA200602058A1 (ru) Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AR074782A1 (es) Antranilamidas sustituidas con tetrazol como plaguicidas
CR8986A (es) Isoxazoles sustituidos como fungicidas
TW200635931A (en) 2,4(4,6)pyrimidine derivatives
EA200601177A1 (ru) Пиридо- и пиримидопиримидиновые производные в качестве антипролиферативных агентов
TW200502225A (en) Heterocyclic compounds useful as nurr-1 activators
UA117151C2 (uk) N-ациліміногетероциклічні сполуки
PE20070041A1 (es) Amidas de acido pirazolcarboxilico
ATE510820T1 (de) Alkoxy-polyester-verbindungen, zusammensetzungen und verwendungsverfahren dafür
MY136824A (en) Substituted benzoxazinones and uses thereof
EA201070817A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-α]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
WO2009027626A3 (en) Improvements in or relating to organic compounds
PY0435702A (es) Mezclas fungicidas a base de derivados de carbamato e insecticidas
MXPA03010436A (es) Amidas biciclicas fusionadas a piridinilo como funguicidas.